Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Oct;85(8):1102–1105. doi: 10.1054/bjoc.2001.2064

Differential p53 protein expression in breast cancer fine needle aspirates: the potential for in vivo monitoring

H M-L Ball 1, T R Hupp 2, D Ziyaie 1, C A Purdie 2, N M Kernohan 2, A M Thompson 1
PMCID: PMC2375165  PMID: 11710820

Abstract

Fine needle aspiration (FNA) biopsy is the least invasive method of sampling breast cancer in vivo and provides material for breast cancer diagnosis. FNA has also been used to examine cellular markers to predict and monitor the effects of therapy. The aim of this study was to assess the accuracy of using FNA material compared with resected cancer for Western blotting studies of the p53 pathway, a key to tumour response to radiotherapy and chemotherapy. Paired samples of breast cancer FNAs collected pre-operatively and post-operatively were compared with tissue samples obtained at the time of surgical resection. Western blots were probed for p53 using the antibodies DO12 and DO1, and for levels of downstream proteins p21/WAF1 and p27. The protein extracted by FNA was sufficient for up to 5 Western blot studies. p53 expression and phosphorylation did not differ significantly pre- and post-operatively, indicating that intra-operative manipulation does not affect p53 expression or downstream activation in breast cancer. However, expression of p53, p21 and p27 varied between individual patients suggesting a range of p53 pathway activation in breast cancer. Immunohistochemistry confirmed that the cancer cells accounted for the protein expression detected on Western blots. FNA yields adequate protein for Western blotting studies and could be used as a method to monitor p53 activity in vivo before and during anti-cancer treatment possibly providing early evidence of tumour response to therapy. © 2001 Cancer Research Campaign  http://www.bjcancer.com

Keywords: FNA (fine needle aspiration), breast cancer, p53, Western blotting

Full Text

The Full Text of this article is available as a PDF (75.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aas T., Børresen A. L., Geisler S., Smith-Sørensen B., Johnsen H., Varhaug J. E., Akslen L. A., Lønning P. E. Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med. 1996 Jul;2(7):811–814. doi: 10.1038/nm0796-811. [DOI] [PubMed] [Google Scholar]
  2. Andersen T. I., Børresen A. L. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection. Diagn Mol Pathol. 1995 Sep;4(3):203–211. doi: 10.1097/00019606-199509000-00008. [DOI] [PubMed] [Google Scholar]
  3. Barbareschi M., Caffo O., Doglioni C., Fina P., Marchetti A., Buttitta F., Leek R., Morelli L., Leonardi E., Bevilacqua G. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer. 1996 Jul;74(2):208–215. doi: 10.1038/bjc.1996.339. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Blaydes J. P., Craig A. L., Wallace M., Ball H. M., Traynor N. J., Gibbs N. K., Hupp T. R. Synergistic activation of p53-dependent transcription by two cooperating damage recognition pathways. Oncogene. 2000 Aug 10;19(34):3829–3839. doi: 10.1038/sj.onc.1203773. [DOI] [PubMed] [Google Scholar]
  5. Blaydes J. P., Hupp T. R. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene. 1998 Aug 27;17(8):1045–1052. doi: 10.1038/sj.onc.1202014. [DOI] [PubMed] [Google Scholar]
  6. Bradford M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 May 7;72:248–254. doi: 10.1016/0003-2697(76)90527-3. [DOI] [PubMed] [Google Scholar]
  7. Brotherick I., Shenton B. K., Lennard T. W. Are fine-needle breast aspirates representative of the underlying solid tumour? A comparison of receptor levels, ploidy and the influence of cytokeratin gates. Br J Cancer. 1995 Sep;72(3):732–737. doi: 10.1038/bjc.1995.402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bueso-Ramos C. E., Manshouri T., Haidar M. A., Yang Y., McCown P., Ordonez N., Glassman A., Sneige N., Albitar M. Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat. 1996;37(2):179–188. doi: 10.1007/BF01806499. [DOI] [PubMed] [Google Scholar]
  9. Craig A. L., Blaydes J. P., Burch L. R., Thompson A. M., Hupp T. R. Dephosphorylation of p53 at Ser20 after cellular exposure to low levels of non-ionizing radiation. Oncogene. 1999 Nov 4;18(46):6305–6312. doi: 10.1038/sj.onc.1203085. [DOI] [PubMed] [Google Scholar]
  10. Elledge R. M., Allred D. C. Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res Treat. 1998;52(1-3):79–98. doi: 10.1023/a:1006163101948. [DOI] [PubMed] [Google Scholar]
  11. Elledge R. M., Lock-Lim S., Allred D. C., Hilsenbeck S. G., Cordner L. p53 mutation and tamoxifen resistance in breast cancer. Clin Cancer Res. 1995 Oct;1(10):1203–1208. [PubMed] [Google Scholar]
  12. Flaman J. M., Frebourg T., Moreau V., Charbonnier F., Martin C., Chappuis P., Sappino A. P., Limacher I. M., Bron L., Benhattar J. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A. 1995 Apr 25;92(9):3963–3967. doi: 10.1073/pnas.92.9.3963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Gudlaugsdottir S., Sigurdardottir V., Snorradottir M., Jonasson J. G., Ogmundsdottir H., Eyfjord J. E. P53 mutations analysis in benign and malignant breast lesions: using needle rinses from fine-needle aspirations. Diagn Cytopathol. 2000 May;22(5):268–274. doi: 10.1002/(sici)1097-0339(200005)22:5<268::aid-dc2>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  14. Hartley M. N., Tuffnell D. J., Hutton J. L., Palmer M., Al-Jafari M. S. Fine needle aspiration cytology: an in vitro study of cell yield. Br J Surg. 1988 Apr;75(4):380–381. doi: 10.1002/bjs.1800750428. [DOI] [PubMed] [Google Scholar]
  15. Haupt Y., Maya R., Kazaz A., Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997 May 15;387(6630):296–299. doi: 10.1038/387296a0. [DOI] [PubMed] [Google Scholar]
  16. Hopwood D., Moitra S., Vojtesek B., Johnston D. A., Dillon J. F., Hupp T. R. Biochemical analysis of the stress protein response in human oesophageal epithelium. Gut. 1997 Aug;41(2):156–163. doi: 10.1136/gut.41.2.156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Jones J. M., Cui X. S., Medina D., Donehower L. A. Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model. Cell Growth Differ. 1999 Apr;10(4):213–222. [PubMed] [Google Scholar]
  18. Kastan M. B., Onyekwere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991 Dec 1;51(23 Pt 1):6304–6311. [PubMed] [Google Scholar]
  19. Kuner R., Pollow K., Lehnert A., Pollow B., Scheler P., Krummenauer F., Casper F., Hoffmann G. Vergleich der biochemischen Analyse verschiedener Prognosefaktoren zwischen Stanzbiopsie und intraoperativ gewonnenem Tumormaterial beim Mammakarzinom. Zentralbl Gynakol. 2000;122(3):160–164. [PubMed] [Google Scholar]
  20. Lavarino C., Corletto V., Mezzelani A., Della Torre G., Bartoli C., Riva C., Pierotti M. A., Rilke F., Pilotti S. Detection of TP53 mutation, loss of heterozygosity and DNA content in fine-needle aspirates of breast carcinoma. Br J Cancer. 1998;77(1):125–130. doi: 10.1038/bjc.1998.20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Linke S. P., Clarkin K. C., Di Leonardo A., Tsou A., Wahl G. M. A reversible, p53-dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev. 1996 Apr 15;10(8):934–947. doi: 10.1101/gad.10.8.934. [DOI] [PubMed] [Google Scholar]
  22. Lowe S. W., Bodis S., McClatchey A., Remington L., Ruley H. E., Fisher D. E., Housman D. E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 1994 Nov 4;266(5186):807–810. doi: 10.1126/science.7973635. [DOI] [PubMed] [Google Scholar]
  23. Makris A., Allred D. C., Powles T. J., Dowsett M., Fernando I. N., Trott P. A., Ashley S. E., Ormerod M. G., Titley J. C., Osborne C. K. Cytological evaluation of biological prognostic markers from primary breast carcinomas. Breast Cancer Res Treat. 1997 May;44(1):65–74. doi: 10.1023/a:1005717924761. [DOI] [PubMed] [Google Scholar]
  24. Nizzoli R., Bozzetti C., Naldi N., Guazzi A., Gabrielli M., Michiara M., Camisa R., Barilli A., Cocconi G. Comparison of the results of immunocytochemical assays for biologic variables on preoperative fine-needle aspirates and on surgical specimens of primary breast carcinomas. Cancer. 2000 Feb 25;90(1):61–66. [PubMed] [Google Scholar]
  25. Pelosi G., Bresaola E., Rodella S., Manfrin E., Piubello Q., Schiavon I., Iannucci A. Expression of proliferating cell nuclear antigen, Ki-67 antigen, estrogen receptor protein, and tumor suppressor p53 gene in cytologic samples of breast cancer: an immunochemical study with clinical, pathobiological, and histologic correlations. Diagn Cytopathol. 1994;11(2):131–140. doi: 10.1002/dc.2840110206. [DOI] [PubMed] [Google Scholar]
  26. Rao J. Y., Apple S. K., Hemstreet G. P., Jin Y., Nieberg R. K. Single cell multiple biomarker analysis in archival breast fine-needle aspiration specimens: quantitative fluorescence image analysis of DNA content, p53, and G-actin as breast cancer biomarkers. Cancer Epidemiol Biomarkers Prev. 1998 Nov;7(11):1027–1033. [PubMed] [Google Scholar]
  27. Sgambato A., Zhang Y. J., Arber N., Hibshoosh H., Doki Y., Ciaparrone M., Santella R. M., Cittadini A., Weinstein I. B. Deregulated expression of p27(Kip1) in human breast cancers. Clin Cancer Res. 1997 Oct;3(10):1879–1887. [PubMed] [Google Scholar]
  28. Sherr C. J., Roberts J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999 Jun 15;13(12):1501–1512. doi: 10.1101/gad.13.12.1501. [DOI] [PubMed] [Google Scholar]
  29. Shiohara M., Koike K., Komiyama A., Koeffler H. P. p21WAF1 mutations and human malignancies. Leuk Lymphoma. 1997 Jun;26(1-2):35–41. doi: 10.3109/10428199709109155. [DOI] [PubMed] [Google Scholar]
  30. Steele R. J., Thompson A. M., Hall P. A., Lane D. P. The p53 tumour suppressor gene. Br J Surg. 1998 Nov;85(11):1460–1467. doi: 10.1046/j.1365-2168.1998.00910.x. [DOI] [PubMed] [Google Scholar]
  31. Stephen C. W., Helminen P., Lane D. P. Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. J Mol Biol. 1995 Apr 21;248(1):58–78. doi: 10.1006/jmbi.1995.0202. [DOI] [PubMed] [Google Scholar]
  32. Tanaka N., Ishihara M., Lamphier M. S., Nozawa H., Matsuyama T., Mak T. W., Aizawa S., Tokino T., Oren M., Taniguchi T. Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. Nature. 1996 Aug 29;382(6594):816–818. doi: 10.1038/382816a0. [DOI] [PubMed] [Google Scholar]
  33. Taxin A., Tartter P. I., Zappetti D. Breast cancer diagnosis by fine needle aspiration and excisional biopsy. Recurrence and survival. Acta Cytol. 1997 Mar-Apr;41(2):302–306. doi: 10.1159/000332516. [DOI] [PubMed] [Google Scholar]
  34. Vojtesek B., Dolezalova H., Lauerova L., Svitakova M., Havlis P., Kovarik J., Midgley C. A., Lane D. P. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene. 1995 Jan 19;10(2):389–393. [PubMed] [Google Scholar]
  35. Ziyaie D., Hupp T. R., Thompson A. M. P53 and breast cancer. Breast. 2000 Oct;9(5):239–246. doi: 10.1054/brst.2000.0199. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES